Clinical Trial Update: Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy [Phase 4]

View source ↗

Summary

Phase 4 study evaluating immunogenicity and safety of MenQuadfi as a booster in toddlers aged 12 to 23 months, regardless of prior infancy priming.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenQuadfi (Meningococcal quadrivalent conjugate vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningococcal Immunisation, Healthy Volunteers | Phase 4 | Status: COMPLETED | Results posted: 2025-09-22